Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

Hiroki Yamaguchi, Naoki Takezako, Kazuteru Ohashi, Koji Oba, Takashi Kumagai, Yasuji Kozai, Hisashi Wakita, Koh Yamamoto, Akira Fujita, Tadahiko Igarashi, Chikashi Yoshida, Kazuma Ohyashiki, Shinichiro Okamoto, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI). However, due to the improved prognosis for CML, problems have arisen from long-term administration of TKI. The present study sought to verify whether more patients could achieve treatment-free remission (TFR) after stopping the administration of dasatinib using dasatinib as frontline treatment. Treatment-naïve chronic phase CML cases were treated with dasatinib as frontline treatment. Dasatinib treatment was stopped for 26 patients who achieved deep molecular response (DMR) within 24 months and were able to maintain DMR for an additional 2 years. Ten patients (38.5%) achieved DMR maintenance after 12 months. Recurrence was confirmed in 16 patients, and the median recurrence-free survival time was 5.1 months. The cumulative DMR rates at six and 12 months after restarting treatment were 84.6% and 100%, respectively. The results of this study demonstrated that the DMR maintenance rate after 12 months was 38.5%, which was not significantly different from previous TKI stop trials. The 2-year dasatinib administration period after reaching DMR did not contribute to improve TFR rates. These results suggest that the type of TKI is not associated with better TFR rates.

Original languageEnglish
Pages (from-to)401-408
Number of pages8
JournalInternational journal of hematology
Volume111
Issue number3
DOIs
Publication statusPublished - 2020 Mar 1

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Treatment-free remission
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, H., Takezako, N., Ohashi, K., Oba, K., Kumagai, T., Kozai, Y., Wakita, H., Yamamoto, K., Fujita, A., Igarashi, T., Yoshida, C., Ohyashiki, K., Okamoto, S., Sakamoto, J., Sakamaki, H., & Inokuchi, K. (2020). Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. International journal of hematology, 111(3), 401-408. https://doi.org/10.1007/s12185-019-02801-z